COMPASS Pathways (NASDAQ:CMPS) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of COMPASS Pathways (NASDAQ:CMPS) in a research report report published on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $11.00 price target on the stock.

A number of other research analysts have also recently weighed in on CMPS. Royal Bank of Canada restated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. HC Wainwright dropped their price target on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, Maxim Group dropped their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways currently has an average rating of “Buy” and a consensus price target of $21.83.

COMPASS Pathways Trading Up 0.3 %

Shares of CMPS stock opened at $3.93 on Thursday. COMPASS Pathways has a fifty-two week low of $3.16 and a fifty-two week high of $12.57. The stock has a market cap of $268.89 million, a P/E ratio of -1.79 and a beta of 2.28. The business has a fifty day simple moving average of $4.06 and a 200-day simple moving average of $5.24. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). On average, analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of COMPASS Pathways

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtus ETF Advisers LLC grew its holdings in COMPASS Pathways by 21.4% in the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company’s stock valued at $61,000 after buying an additional 2,840 shares during the period. Conservest Capital Advisors Inc. grew its holdings in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares during the period. Kennedy Capital Management LLC grew its holdings in COMPASS Pathways by 22.8% in the 4th quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company’s stock valued at $128,000 after buying an additional 6,297 shares during the period. Barclays PLC grew its holdings in COMPASS Pathways by 2.1% in the 4th quarter. Barclays PLC now owns 419,194 shares of the company’s stock valued at $1,585,000 after buying an additional 8,718 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in COMPASS Pathways by 15.4% in the 4th quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company’s stock valued at $257,000 after buying an additional 9,099 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.